Upcoming event
17th Meeting of the European Section of Oncological Urology (ESOU20)
Back

Tags

Show all

Testing the external validity of CARMENA trial comparing sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma

View

Predicting Functional Outcomes after Partial Nephrectomy

May 2019

View

Impact of tumor size on cancer specific mortality after local tumor ablation in T1a renal cell carcinoma

Journal of Endourology, April 2019

View

Clinical utility of the mutational landscape and fragment size of circulating tumor DNA in renal cell carcinoma

March 2019

View
webcasts posters

The role of non-tumour renal biopsy in patients treated with radical nephrectomy

March 2019

View
webcasts

Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal call carcinoma patients

March 2019

View
webcasts posters

Identification of a microRNA profile in urine with diagnostic and prognostic value for clear cell renal cell carcinoma

March 2019

View
webcasts posters

Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

View

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143)

View

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study

View

Should partial nephrectomy be considered “elective” in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomy

World Journal of Urology, February 2019

View

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma

January, 2019

View
PreviousNext